Evidence map›Paper›PMID 33079180›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2021

Clinical Characteristics and Outcomes of Coronavirus Disease 2019 Patients Who Received Compassionate-Use Leronlimab.

Bryant Yang, Jennifer A Fulcher, Jenny Ahn, Marlene Berro, David Goodman-Meza, Kush Dhody, Jonah B Sacha, Arash Naeim, Otto O Yang

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. COVID-19 Therapeutics: Use, Mechanism of Action, and Toxicity (Vaccines, Monoclonal Antibodies, and Immunotherapeutics).Journal of medical toxicology : official journal of the American College of Medical Toxicology · 2023
    Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Current trends in diagnosis and treatment strategies of COVID-19 infection.Environmental science and pollution research international · 2021
    Review
  13. Review
  14. Darunavir ethanolate: Repurposing an anti-HIV drug in COVID-19 treatment.European journal of medicinal chemistry reports · 2021
    Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Bryant YangDivision of Infectious Diseases, Department of Medicine, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, California, USA.
Jennifer A FulcherDivision of Infectious Diseases, Department of Medicine, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, California, USA.
Jenny AhnClinical and Translational Science Institute Office of Clinical Research, Department of Medicine, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, California, USA.
Marlene BerroClinical and Translational Science Institute Office of Clinical Research, Department of Medicine, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, California, USA.
David Goodman-MezaDivision of Infectious Diseases, Department of Medicine, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, California, USA.
Kush DhodyAmarex Clinical Research, LLC, Germantown, Maryland, USA.
Jonah B SachaVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.
Arash NaeimClinical and Translational Science Institute Office of Clinical Research, Department of Medicine, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, California, USA.
Otto O YangDivision of Infectious Diseases, Department of Medicine, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, California, USA.
University of California, Los Angeles · USOregon National Primate Research Center · USSouthern California Clinical and Translational Science Institute · USVA Greater Los Angeles Healthcare System · US

Funding

UCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1M
NCATS NIH HHS UL1 TR001881NIH HHS UL1TR001881
6 · The paper itself

Abstract

backgroundLeronlimab, a monoclonal antibody blocker of C-C chemokine receptor type 5 originally developed to treat human immunodeficiency virus infection, was administered as an open-label compassionate-use therapeutic for coronavirus disease 2019 (COVID-19).

methodsTwenty-three hospitalized severe/critical COVID-19 patients received 700 mg leronlimab subcutaneously, repeated after 7 days in 17 of 23 patients still hospitalized. Eighteen of 23 received other experimental treatments, including convalescent plasma, hydroxychloroquine, steroids, and/or tocilizumab. Five of 23 received leronlimab after blinded, placebo-controlled trials of remdesivir, sarilumab, selinexor, or tocilizumab. Outcomes and results were extracted from medical records.

resultsMean age was 69.5 ± 14.9 years; 20 had significant comorbidities. At baseline, 22 were receiving supplemental oxygen (3 high flow, 7 mechanical ventilation). Blood showed markedly elevated inflammatory markers (ferritin, D-dimer, C-reactive protein) and an elevated neutrophil-to-lymphocyte ratio. By day 30 after initial dosing, 17 were recovered, 2 were still hospitalized, and 4 had died. Of the 7 intubated at baseline, 4 were fully recovered off oxygen, 2 were still hospitalized, and 1 had died.

conclusionsLeronlimab appeared safe and well tolerated. The high recovery rate suggested benefit, and those with lower inflammatory markers had better outcomes. Some, but not all, patients appeared to have dramatic clinical responses, indicating that unknown factors may determine responsiveness to leronlimab. Routine inflammatory and cell prognostic markers did not markedly change immediately after treatment, although interleukin-6 tended to fall. In some persons, C-reactive protein clearly dropped only after the second leronlimab dose, suggesting that a higher loading dose might be more effective. Future controlled trials will be informative.

Indexed as

COVID-19AgedAged, 80 and overAntibodies, Monoclonal, HumanizedCOVID-19 SerotherapyHIV AntibodiesHumansImmunization, PassiveMiddle AgedSARS-CoV-2Treatment OutcomeAntibodies, Monoclonal, HumanizedHIV AntibodiesleronlimabCOVID-19immunomodulatory therapyleronlimabSARS-CoV-2

Identifiers

PMID33079180
PMCPMC7665416
OpenAlexW3093398205

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.